Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartame SCHEMBL19283498 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Aspartame SCHEMBL10625481 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Aspartame SCHEMBL900809 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Aspartame SCHEMBL216238 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Aspartame SCHEMBL3637 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Aspartame SCHEMBL10635593 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Aspartame SCHEMBL11085391 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Aspartame SCHEMBL8091203 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Aspartame SCHEMBL8761655 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Aspartame SCHEMBL3636 | 1.00 | ALDH1A1 (0.64) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0976761-B1 | Isolation of crystals of alpha-L-aspartyl-L-phenylalanine methyl ester | DAESANG CORP (KR) | 2003-05-21 | — | — | EP | claimed |
| JP-60048920-A | — | — | None | — | — | JP | disclosed |
| EP-1658079-B1 | MULTIVITAMIN SYRUP FOR CHILDREN OR YOUNG ADULTS | PHARMATON SA (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20120093803-A1 | MEANS AND METHODS OF STERILIZATION OF BIOFUNCTIONAL COMPOSITIONS | LEUKOCARE AG (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120058166-A1 | FILAMENTS COMPRISING A NON-PERFUME ACTIVE AGENT NONWOVEN WEBS AND METHODS FOR MAKING SAME | GLENN JR ROBERT WAYNE (US) | 2012-03-08 | — | — | US | disclosed |
| EP-2424621-A2 | METHODS FOR IMPROVING TASTE AND ORAL CARE COMPOSITIONS WITH IMPROVED TASTE | The Procter & Gamble Company (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120052101-A1 | THIN FILM STRIPS | BERRY CRAIG (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053108-A1 | METHOD FOR DELIVERING AN ACTIVE AGENT | GLENN JR ROBERT WAYNE (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120048769-A1 | PROCESS FOR MAKING FILMS FROM NONWOVEN WEBS | SIVIK MARK ROBERT (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120052036-A1 | FILAMENTS COMPRISING AN ACTIVE AGENT NONWOVEN WEBS AND METHODS FOR MAKING SAME | GLENN JR ROBERT WAYNE (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011020610-A1 | DRUG DELIVERY SYSTEMS (WAFER) FOR PEDIATRIC USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011018482-A1 | STABILISED PARTICLES COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLATE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011014401-A2 | ORAL CARE ARTICLES AND METHODS | THE PROCTER & GAMBLE COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110027328-A1 | Oral Care Articles and Methods | THE PROCTER & GAMBLE COMPANY | 2011-02-03 | — | — | US | disclosed |
| US-20110020456-A1 | LANTHANUM COMPOSITION | MYLAN LABORATORIES LIMITED (IN) | 2011-01-27 | — | — | US | disclosed |
| US-7867509-B2 | Fast dissolving orally consumable films | JOHNSON & JOHNSON CONSUMER INC. | 2011-01-11 | — | — | US | disclosed |
| EP-2268258-A1 | ORAL CARE COMPOSITIONS | The Procter & Gamble Company (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-0157873-B2 | DIETETIC FROZEN DESSERTS CONTAINING ASPARTAME | WOLKSTEIN MELVIN (US) | 1996-04-17 | — | — | EP | disclosed |
| US-4626441-A | WITH SYNERGISTIC SWEETENERS AND BULKING AGENT | WOLKSTEIN MELVIN (US) | 1986-12-02 | — | — | US | disclosed |
| JP-S6048920-A | ORAL AGENT CONTAINING DIPEPTIDE SWEETENER | AJINOMOTO CO INC | 1985-03-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110027328-A1 | Oral Care Articles and Methods | STOM, DSC1, DSG1 | ALDH1A1 4428/4885THRB 4744/4885CYP2C9 2123/4885 |
| US-20120052036-A1 | FILAMENTS COMPRISING AN ACTIVE AGENT NONWOVEN WEBS AND METHODS FOR MAKING SAME | VCL, KRT18, TPM4 | ALDH1A1 4451/4885THRB 4484/4885CYP2C9 4871/4885 |
| US-20120058166-A1 | FILAMENTS COMPRISING A NON-PERFUME ACTIVE AGENT NONWOVEN WEBS AND METHODS FOR MAKING SAME | KRT18, FLNA, NEFM | ALDH1A1 4055/4885THRB 4644/4885CYP2C9 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.